NASDAQ:MGTX MeiraGTx (MGTX) Stock Price, News & Analysis $9.87 -0.03 (-0.32%) As of 01:50 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About MeiraGTx Stock (NASDAQ:MGTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MeiraGTx alerts:Sign Up Key Stats Today's Range$9.62▼$9.9150-Day Range$6.99▼$11.2952-Week Range$4.55▼$11.85Volume152,413 shsAverage Volume596,599 shsMarket Capitalization$913.48 millionP/E RatioN/ADividend YieldN/APrice Target$25.67Consensus RatingModerate Buy Company Overview MeiraGTx Holdings plc is a clinical-stage biotechnology company dedicated to developing gene therapies for the treatment of rare diseases. Founded in 2014 as an outgrowth of research at University College London, the company focuses on leveraging adeno-associated virus (AAV) vectors to deliver functional genes to target tissues. MeiraGTx’s pipeline spans ocular, central nervous system and systemic indications, addressing conditions such as inherited retinal dystrophies and neurodegenerative disorders that currently lack effective therapies. The company’s lead programs include AAV-based candidates designed to restore or replace defective genes underlying rare retinal diseases and to modulate cellular pathways in neurological disorders. MeiraGTx has established an end-to-end platform encompassing vector design, process development, and manufacturing scale-up, with capabilities housed in facilities across the United Kingdom and the United States. This integrated approach aims to accelerate the transition from preclinical research to clinical trials and, ultimately, patient access. MeiraGTx completed its initial public offering on the Nasdaq in April 2018 and operates research laboratories in London alongside a manufacturing and clinical operations center in the New York metropolitan area. The company’s leadership team comprises industry veterans with extensive experience in gene therapy development, regulatory affairs and commercialization. MeiraGTx continues to advance its clinical programs in collaboration with academic institutions and contract research organizations, targeting global patient populations in need of novel therapeutic options.AI Generated. May Contain Errors. Read More MeiraGTx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks54th Percentile Overall ScoreMGTX MarketRank™: MeiraGTx scored higher than 54% of companies evaluated by MarketBeat, and ranked 422nd out of 863 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingMeiraGTx has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 1 strong buy rating, 5 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialMeiraGTx has a consensus price target of $25.67, representing about 164.8% upside from its current price of $9.69.Amount of Analyst CoverageMeiraGTx has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about MeiraGTx's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for MeiraGTx are expected to decrease in the coming year, from ($1.76) to ($1.87) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MeiraGTx is -6.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MeiraGTx is -6.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about MeiraGTx's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.69% of the float of MeiraGTx has been sold short.Short Interest Ratio / Days to CoverMeiraGTx has a short interest ratio ("days to cover") of 4.29.Change versus previous monthShort interest in MeiraGTx has recently increased by 23.85%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMeiraGTx does not currently pay a dividend.Dividend GrowthMeiraGTx does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.38 News SentimentMeiraGTx has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for MeiraGTx this week, compared to 2 articles on an average week.Search Interest14 people have searched for MGTX on MarketBeat in the last 30 days. This is an increase of 180% compared to the previous 30 days.MarketBeat Follows3 people have added MeiraGTx to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, MeiraGTx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,290,647.00 in company stock.Percentage Held by Insiders7.50% of the stock of MeiraGTx is held by insiders.Percentage Held by Institutions67.48% of the stock of MeiraGTx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about MeiraGTx's insider trading history. Receive MGTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MeiraGTx and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MGTX Stock News HeadlinesMeiraGTx (MGTX) Projected to Post Earnings on TuesdayMay 10 at 3:34 AM | americanbankingnews.comEvercore Maintains Positive Stance on MeiraGTx Holdings plc (MGTX) Amid Sector RevisionsApril 18, 2026 | finance.yahoo.comIf You Have $50k+ on Coinbase, This Will Ruin Your DayIn 2009, Greece's debt-to-GDP ratio hit 130%. Within 24 months... Pensions were slashed 40% overnight. Bank accounts were frozen. ATMs were capped at roughly €60 per day. That was at 130%. The IMF now projects the United States will hit 143.4% debt-to-GDP by 2035. When Greece collapsed... the EU and IMF swooped in with $300 billion in bailouts. When America crosses that line... there is no bigger economy to save us. "But surely the government has a plan?" This Wednesday May 13th. I'm going to show you exactly what that plan is... and how i's going to create the single biggest wealth transfer of our generation.May 12 at 1:00 AM | Decentralized Masters (Ad)Eli Lilly partner MeiraGTx regains rights for genetic eye disease drug from Johnson & JohnsonApril 16, 2026 | msn.comMeiraGTx eyes $100M equity offering after gene therapy deal with J&JApril 16, 2026 | msn.comMeiraGTx Holdings plc (MGTX) Discusses 3-Year Phase I Data on AAV-hAQP1 for Radiation-Induced Xerostomia and Commercial Opportunity TranscriptApril 16, 2026 | seekingalpha.comMeiraGTx Holdings plc (MGTX) Discusses 3-Year Phase I Data on AAV-hAQP1 for Radiation-Induced Xerostomia and Commercial Opportunity - SlideshowApril 16, 2026 | seekingalpha.comMeiraGTx Announces Pricing of $100 Million Offering of Ordinary SharesApril 16, 2026 | globenewswire.comSee More Headlines MGTX Stock Analysis - Frequently Asked Questions How have MGTX shares performed this year? MeiraGTx's stock was trading at $7.95 on January 1st, 2026. Since then, MGTX shares have increased by 21.9% and is now trading at $9.6940. How were MeiraGTx's earnings last quarter? MeiraGTx Holdings PLC (NASDAQ:MGTX) released its quarterly earnings data on Thursday, March, 26th. The company reported $0.19 earnings per share for the quarter, beating the consensus estimate of ($0.60) by $0.79. The firm earned $75.36 million during the quarter, compared to the consensus estimate of $3.87 million. MeiraGTx had a negative trailing twelve-month return on equity of 1,065.47% and a negative net margin of 140.31%. When did MeiraGTx IPO? MeiraGTx (MGTX) raised $75 million in an IPO on Friday, June 8th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Barclays and Evercore ISI served as the underwriters for the IPO and Chardan was co-manager. Who are MeiraGTx's major shareholders? MeiraGTx's top institutional investors include AlphaCentric Advisors LLC (0.06%) and Hsbc Holdings PLC (0.05%). Insiders that own company stock include Perceptive Advisors Llc, Alexandria Forbes, Richard Giroux and Stuart Naylor. View institutional ownership trends. How do I buy shares of MeiraGTx? Shares of MGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MeiraGTx own? Based on aggregate information from My MarketBeat watchlists, some other companies that MeiraGTx investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Moderna (MRNA). Company Calendar Last Earnings3/26/2026Today5/12/2026Next Earnings (Estimated)5/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (11m+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 MGTX's financial health is in the Green zone, according to TradeSmith. MGTX has been in this zone for over 11 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MGTX CIK1735438 Webwww.meiragtx.com Phone(646) 860-7985FaxN/AEmployees300Year Founded2015Price Target and Rating Average Price Target for MeiraGTx$25.67 High Price Target$35.00 Low Price Target$16.00 Potential Upside/Downside+160.1%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($1.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$114.20 million Net Margins-140.31% Pretax Margin-140.31% Return on Equity-1,065.47% Return on Assets-53.33% Debt Debt-to-Equity RatioN/A Current Ratio0.75 Quick Ratio0.75 Sales & Book Value Annual Sales$81.39 million Price / Sales11.22 Cash FlowN/A Price / Cash FlowN/A Book Value($0.07) per share Price / Book-140.97Miscellaneous Outstanding Shares92,570,000Free Float85,631,000Market Cap$913.48 million OptionableOptionable Beta1.23 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:MGTX) was last updated on 5/12/2026 by MarketBeat.com Staff. From Our PartnersNNVC FDA = New Momentum Wave!NanoViricides (NYSE: NNVC) just received FDA Orphan Drug Designation for NV-387, its antiviral candidate targe...Equiscreen | SponsoredRise of the… petroyuan?On February 28th, Iran installed a yuan-denominated toll at the Strait of Hormuz - the chokepoint for one in e...Golden Portfolio | SponsoredBSEM: From OTC to Nasdaq Contender!BioStem Technologies (OTC: BSEM) has posted seven consecutive profitable quarters and just released audited fi...Huge Alerts | SponsoredRead this or regret it foreverThree Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredIf You Have $50k+ on Coinbase, This Will Ruin Your DayIn 2009, Greece's debt-to-GDP ratio hit 130%. Within 24 months... Pensions were slashed 40% overnight. Bank ac...Decentralized Masters | SponsoredSpaceX Launches Strange 'Dark Energy' Across AmericaSpaceX is deploying a newly permitted energy technology - one that analyst Joel Litman calls 'Dark Energy' - t...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MeiraGTx Holdings PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share MeiraGTx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
